New asthma drug shows promise in Mid-Stage trial
Disease control
Not yet recruiting
This study tests a new drug called frevecitinib (KN-002) in 512 adults with severe asthma that is not well controlled by their current inhalers. Participants will receive one of three doses of the drug or a placebo for 12 weeks. The goal is to see if the drug improves lung functi…
Phase: PHASE2 • Sponsor: Kinaset Therapeutics Inc • Aim: Disease control
Last updated May 10, 2026 11:54 UTC